On Monday, Janux Therapeutics Inc (NASDAQ: JANX) opened lower -11.13% from the last session, before settling in for the closing price of $45.21. Price fluctuations for JANX have ranged from $7.79 to $65.60 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 32.66%. Company’s average yearly earnings per share was noted -4.77% at the time writing. With a float of $42.67 million, this company’s outstanding shares have now reached $52.34 million.
The extent of productivity of a business whose workforce counts for 64 workers is very important to gauge. In terms of profitability, gross margin is 87.98%, operating margin of -658.76%, and the pretax margin is -463.91%.
Janux Therapeutics Inc (JANX) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Janux Therapeutics Inc is 18.75%, while institutional ownership is 86.63%. The most recent insider transaction that took place on Nov 25 ’24, was worth 1,289,879. In this transaction President and CEO of this company sold 25,000 shares at a rate of $51.60, taking the stock ownership to the 257,054 shares. Before that another transaction happened on Nov 01 ’24, when Company’s FORMER OFFICER proposed sale 5,202 for $53.44, making the entire transaction worth $277,987.
Janux Therapeutics Inc (JANX) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.25 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.39) by 0.14. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.47 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -4.77% per share during the next fiscal year.
Janux Therapeutics Inc (NASDAQ: JANX) Trading Performance Indicators
Check out the current performance indicators for Janux Therapeutics Inc (JANX). In the past quarter, the stock posted a quick ratio of 38.80. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 157.48.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.18, a number that is poised to hit -0.41 in the next quarter and is forecasted to reach -1.95 in one year’s time.
Technical Analysis of Janux Therapeutics Inc (JANX)
The latest stats from [Janux Therapeutics Inc, JANX] show that its last 5-days average volume of 1.17 million was superior to 0.72 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 2.85%. Additionally, its Average True Range was 3.08.
During the past 100 days, Janux Therapeutics Inc’s (JANX) raw stochastic average was set at 24.07%, which indicates a significant increase from 1.08% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 63.44% in the past 14 days, which was higher than the 57.23% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $49.68, while its 200-day Moving Average is $44.82. Now, the first resistance to watch is $44.05. This is followed by the second major resistance level at $47.91. The third major resistance level sits at $49.93. If the price goes on to break the first support level at $38.17, it is likely to go to the next support level at $36.15. Assuming the price breaks the second support level, the third support level stands at $32.28.
Janux Therapeutics Inc (NASDAQ: JANX) Key Stats
There are currently 52,482K shares outstanding in the company with a market cap of 2.06 billion. Presently, the company’s annual sales total 8,080 K according to its annual income of -58,290 K. Last quarter, the company’s sales amounted to 440 K and its income totaled -28,060 K.
